R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

R&G PharmaStudies Co Ltd
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Selling, General & Administrative
-ÂĄ101.6m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Selling, General & Administrative
-ÂĄ3.7B
CAGR 3-Years
-12%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Selling, General & Administrative
-ÂĄ1.9B
CAGR 3-Years
-30%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Selling, General & Administrative
-ÂĄ2.4B
CAGR 3-Years
-33%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Selling, General & Administrative
-ÂĄ929.9m
CAGR 3-Years
-14%
CAGR 5-Years
-18%
CAGR 10-Years
-24%
W
WuXi XDC Cayman Inc
HKEX:2268
Selling, General & Administrative
-ÂĄ117.2m
CAGR 3-Years
-141%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
57.24 CNY
Overvaluation 2%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Selling, General & Administrative?
Selling, General & Administrative
-101.6m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Selling, General & Administrative amounts to -101.6m CNY.

What is R&G PharmaStudies Co Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 3Y
-15%

Over the last year, the Selling, General & Administrative growth was -27%. The average annual Selling, General & Administrative growth rates for R&G PharmaStudies Co Ltd have been -15% over the past three years .

Back to Top